Skip to main content
Haematologica logoLink to Haematologica
. 2024 Jan 1;109(1):365. doi: 10.3324/haematol.2023.284289

Erratum to: DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome

Kerry J Savage 1,2,, Graham W Slack 1,3
PMCID: PMC10772485  PMID: 38186344

We made non-substantive typographical corrections and the following substantive changes to the original figure of our editorial “DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome”1: WHO 2nd edition 2001 is changed to WHO 3rd edition 2001; WHO 3rd edition 2008 is changed to WHO 4th edition 2008; and WHO 4th edition 2016 is changed to WHO Revised 4th edition 2016.

Figure 1.

Figure 1.

Current classification of systemic anaplastic large cell lymphoma. The most common t(2;5) (ALK-NPM) is shown. Rare variant rearrangements involving the ALK gene on 2p23 and different partner genes on other chromosomes can occur in 15-25% of cases of ALK-positive anaplastic large cell lymphoma. ALCL: anaplastic large cell lymphoma; WHO: World Health Organization; ALK: anaplastic lymphoma kinase.

References

  • 1.Savage KJ, Slack GW. DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome. Haematologica. 2023;108(6):1463-1467. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Haematologica are provided here courtesy of Ferrata Storti Foundation

RESOURCES